MIRM Key Statistics, Chart & Performance
The current stock price of MIRM is 79.795 USD. In the past month the price increased by 14.23%. In the past year, price increased by 95.07%.
MIRM Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.18 | 403.89B | ||
| AMGN | AMGEN INC | 15.13 | 178.15B | ||
| GILD | GILEAD SCIENCES INC | 15.26 | 155.01B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.45 | 116.51B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.45 | 82.53B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 778.94 | 52.48B | ||
| INSM | INSMED INC | N/A | 37.83B | ||
| NTRA | NATERA INC | N/A | 32.68B | ||
| BIIB | BIOGEN INC | 10.45 | 25.67B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.34 | 21.97B | ||
| INCY | INCYTE CORP | 15.67 | 19.75B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.31B |
Related stock screener links
About MIRM
Company Profile
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The company is headquartered in Foster City, California and currently employs 355 full-time employees. The company went IPO on 2019-07-18. The firm is focused on the treatment of rare diseases affecting children and adults. The company has three medicines: LIVMARLI (maralixibat) oral solution (Livmarli), Cholbam (cholic acid) capsules, and Chenodal or Ctexli (chenodiol) tablets. Livmarli is an orally administered, minimally-absorbed ileal bile acid transporter (IBAT) inhibitor (IBATi) that is used for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) in the United States and various other countries and for cholestatic pruritus in patient with progressive familial intrahepatic cholestasis (PFIC) in the United States. Cholbam is used for the treatment of bile acid synthesis disorders due to single enzyme deficiencies and adjunctive treatment of peroxisomal disorders. The firm is also advancing its product candidate, volixibat, for the treatment of adult patients with cholestatic liver diseases.
Company Info
MIRUM PHARMACEUTICALS INC
989 East Hillsdale Boulevard, Suite 300
Foster City CALIFORNIA 94404 US
CEO: Christopher Peetz
Employees: 322
Phone: 16506674085
MIRUM PHARMACEUTICALS INC / MIRM FAQ
What does MIRM do?
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The company is headquartered in Foster City, California and currently employs 355 full-time employees. The company went IPO on 2019-07-18. The firm is focused on the treatment of rare diseases affecting children and adults. The company has three medicines: LIVMARLI (maralixibat) oral solution (Livmarli), Cholbam (cholic acid) capsules, and Chenodal or Ctexli (chenodiol) tablets. Livmarli is an orally administered, minimally-absorbed ileal bile acid transporter (IBAT) inhibitor (IBATi) that is used for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) in the United States and various other countries and for cholestatic pruritus in patient with progressive familial intrahepatic cholestasis (PFIC) in the United States. Cholbam is used for the treatment of bile acid synthesis disorders due to single enzyme deficiencies and adjunctive treatment of peroxisomal disorders. The firm is also advancing its product candidate, volixibat, for the treatment of adult patients with cholestatic liver diseases.
What is the stock price of MIRUM PHARMACEUTICALS INC today?
The current stock price of MIRM is 79.795 USD. The price decreased by -1.57% in the last trading session.
What is the dividend status of MIRUM PHARMACEUTICALS INC?
MIRM does not pay a dividend.
What is the ChartMill rating of MIRUM PHARMACEUTICALS INC stock?
MIRM has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
Can you provide the sector and industry classification for MIRUM PHARMACEUTICALS INC?
MIRUM PHARMACEUTICALS INC (MIRM) operates in the Health Care sector and the Biotechnology industry.
Can you provide the market cap for MIRUM PHARMACEUTICALS INC?
MIRUM PHARMACEUTICALS INC (MIRM) has a market capitalization of 4.10B USD. This makes MIRM a Mid Cap stock.
Can you provide the short interest for MIRM stock?
The outstanding short interest for MIRUM PHARMACEUTICALS INC (MIRM) is 17.16% of its float.
MIRM Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to MIRM. When comparing the yearly performance of all stocks, MIRM is one of the better performing stocks in the market, outperforming 93.75% of all stocks.
MIRM Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to MIRM. MIRM scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
MIRM Financial Highlights
Over the last trailing twelve months MIRM reported a non-GAAP Earnings per Share(EPS) of -0.86. The EPS increased by 57.43% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -5.3% | ||
| ROE | -14.26% | ||
| Debt/Equity | 1.06 |
MIRM Forecast & Estimates
16 analysts have analysed MIRM and the average price target is 104.35 USD. This implies a price increase of 30.77% is expected in the next year compared to the current price of 79.795.
For the next year, analysts expect an EPS growth of 78.72% and a revenue growth 51.86% for MIRM